MannKind Corporation (FRA:NNFN)

Germany flag Germany · Delayed Price · Currency is EUR
4.649
+0.097 (2.13%)
At close: Feb 20, 2026
Market Cap1.44B -3.3%
Revenue (ttm)267.44M +17.4%
Net Income24.92M +35.5%
EPS0.08 +23.5%
Shares Outn/a
PE Ratio57.95
Forward PE28.76
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume88
Open4.649
Previous Close4.552
Day's Range4.649 - 4.649
52-Week Range2.925 - 5.500
Betan/a
RSI47.37
Earnings DateFeb 26, 2026

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1991
Employees 405
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol NNFN
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements